[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"posterior-circulation-brain-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:posterior-circulation-brain-infarction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100550912","predictors-of-intracranial-atherosclerotic-disease-in-posterior-circulation-a-cohort-study-100550912",false,"NCT06453252","Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study","Inclusion Criteria:\n\n1. Adult ≥18 years\n2. Patient with posterior circulation strokes who underwent mechanical thrombectomy.\n\nExclusion Criteria:\n\n1. Patients with anterior circulation stroke.\n2. Patients with intracranial hemorrhage\n3. Patients without baseline radiological data.\n4. Extracranial large vessel atherosclerosis related strokes.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","OBSERVATIONAL","Early identification of intracranial atherosclerotic disease (ICAD) may impact the management of patients undergoing mechanical thrombectomy (MT). The aim of the study is to develop and validate a scoring system for pre-thrombectomy diagnosis of ICAD in posterior circulation large vessel\u002Fdistal medium vessel occlusion strokes (LVOs\u002FDMVOs).",[23,24,25],"Stroke, Ischemic","Intracranial Atherosclerosis","Posterior Circulation Brain Infarction","NOT_YET_RECRUITING","2024-07-09",{"date":29,"type":30},"2024-07-10","ACTUAL",{"date":32,"type":19},"2024-08-01",{"date":34,"type":19},"2026-06-30",{"name":36,"class":37},"Sohag University","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100553733","early-phase-1-cerebrolysin-as-an-add-on-therapy-to-standard-treatment-of-basilar-artery-occlusion-100553733","NCT06489925","Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion","Cerebrolysin as an Add-On Therapy to Standard Treatment of Posterior Circulation Stroke Secondary to Basilar Artery Occlusion","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Acute basilar artery occlusion confirmed on MSCT\u002F MR angiography\n* Premorbid mRS ≤ 3\n* Signed written consent\n\nExclusion Criteria:\n\n* Hypersensitivity to one of the components of the drug\n* Breastfeeding and pregnancy\n* Epilepsy, epileptic seizure\n* Severe renal impairment (grade IV and V)\n* Ischemic stroke in the previous three months\n* Metastatic cancer\n* Sepsis or a severe infection on admission\n* Acute coronary syndrome, pulmonary embolism, and deep venous thrombosis on admission",{"count":46,"type":19},20,"INTERVENTIONAL",[49],"EARLY_PHASE1","The standard therapy for acute ischemic posterior circulation stroke (PCS) often leads to poor functional outcomes and high mortality rates, despite all advances in reperfusion therapy. Recent trials have shown that adding Cerebrolysin, a cerebral neuroprotective agent, to standard therapy for patients with acute ischemic anterior circulation stroke is safe and leads to improved functional outcomes. The purpose of this study is to assess the effectiveness and safety of Cerebrolysin with standard treatment for patients with PCS secondary to basilar artery occlusion (BAO).\n\nThe plan is to conduct a prospective, single-center, single-arm, open-label study with 20 acute basilar artery occlusion patients and premorbid modified Rankin Score (mRS) ≤3, treated with standard treatment (mechanical thrombectomy ± intravenous alteplase or conservative treatment) and Cerebrolysin as add-on therapy, compared with historical controls. Besides standard acute stroke assessment, standard treatment, and rehabilitation, the participants who meet the eligibility criteria will receive Cerebrolysin in a single-day dosage of 30 ml intravenously for 14 consecutive days. The participants will be closely monitored, and neuroimaging findings and clinical outcomes will be obtained during the drug administration period, on discharge, one month, and 3 months after the treatment onset.\n\nThe primary endpoints are mRS (0-3) on day 90 and mortality rate 90 days after the stroke onset. The secondary endpoints are defined as a change in any type of intracerebral bleeding and a change of min. 2 points on the National Institutes of Health Stroke Scale 24 hours, 14 days, 30 days, and 90 days post-stroke.\n\nThe investigators hypothesize that adding Cerebrolysin to standard stroke treatment will improve clinical outcomes and reduce morbidity and mortality in patients with acute basilar occlusion compared to standard treatment alone.",[52,25],"Basilar Artery Occlusion",[54,55,56,57,58],"Cerebrolysin","neuroprotection","basilar artery occlusion","add-on therapy","posterior circulation stroke","2024-07-08",{"date":27,"type":30},{"date":62,"type":19},"2024-07",{"date":64,"type":19},"2026-05",{"name":66,"class":37},"University Hospital Sestre Milosrdnice"]